Almanack Investment Partners LLC. Takes Position in ASP Isotopes Inc. (NASDAQ:ASPI)

Almanack Investment Partners LLC. purchased a new stake in shares of ASP Isotopes Inc. (NASDAQ:ASPI) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 15,050 shares of the company’s stock, valued at approximately $68,000.

Other large investors also recently modified their holdings of the company. Fiera Capital Corp purchased a new position in ASP Isotopes during the third quarter valued at $723,000. GSA Capital Partners LLP grew its holdings in shares of ASP Isotopes by 96.0% in the third quarter. GSA Capital Partners LLP now owns 770,989 shares of the company’s stock worth $2,143,000 after acquiring an additional 377,721 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in ASP Isotopes during the third quarter valued at approximately $6,249,000. Charles Schwab Investment Management Inc. raised its stake in shares of ASP Isotopes by 16.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 120,278 shares of the company’s stock worth $334,000 after buying an additional 17,159 shares during the period. Finally, Telemark Asset Management LLC bought a new position in ASP Isotopes in the 3rd quarter worth $4,726,000. 16.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and set a $4.50 price target on shares of ASP Isotopes in a research note on Friday, October 18th.

ASP Isotopes Stock Up 7.5 %

Shares of ASPI stock opened at $6.19 on Friday. The company has a market cap of $441.90 million, a price-to-earnings ratio of -10.15 and a beta of 3.51. ASP Isotopes Inc. has a 1-year low of $1.86 and a 1-year high of $9.33. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.55 and a quick ratio of 7.54. The stock’s fifty day moving average price is $5.15 and its 200 day moving average price is $4.34.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.